Abstract
Bacillus Calmette-Guerin (BCG) intravesical instillation therapy has been established as a standard of care treatment for high-risk non-muscle invasive urothelial carcinoma (NMIUC). To date, many clinical have demonstrated a direct antitumor activity, prevention of tumor recurrence, reductions in tumor progression and, consequently, tumor specific mortality and improvement in overall survival. Nevertheless, the local adverse events arising from BCG intravesical account for about one-third of treatment discontinuations. Strategies to minimize the side effects are needed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
